Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Target Price
The average target price of EVT.DE is 4.52 and suggests 61.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in